Moderate-to-severe Chronic Plaque Psoriasis study: Ponesimod
Official title Open Label Study to Investigate the Safety and Efficacy of Ponesimod in Moderate-to-Severe Chronic Plaque Psoriasis
ClinicalTrials.gov ID: NCT07362017
What this study is testing
What is Ponesimod?
An investigational oral tablet being studied as a potential treatment for moderate-to-severe chronic plaque psoriasis. It is designed to modulate sphingosine‑1‑phosphate receptors, which reduces the movement of certain immune cells out of lymph nodes.
Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This study is testing whether ponesimod is safe and works for moderate‑to‑severe chronic plaque psoriasis.
- Who it's for
- You may be able to join if you have moderate‑to‑severe chronic plaque psoriasis.
- What's involved
- You will take ponesimod at home and have visits to check your skin and health.
- Time commitment
- The study lasts several months with regular check‑ins.
- Phase 3: a large, late-stage study
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 65
You may be able to join if
- Male and female people aged 18-65 years, inclusive
- BMI \>18 and \<40
- Minimum affected BSA of 10%
- PASI score ≥ 12
- PGA ≥ 3
You likely can't join if
- Diagnosis of generalized erythrodermic, generalized pustular (von Zumbusch), guttate, or palmoplantar psoriasis
- History of an allergic reaction or known and/or significant sensitivity to study drug
See the full eligibility criteria
- Male and female people aged 18-65 years, inclusive
- BMI \>18 and \<40
- Minimum affected BSA of 10%
- PASI score ≥ 12
- PGA ≥ 3
- Diagnosed with moderate-to-severe plaque psoriasis
- Diagnosis of generalized erythrodermic, generalized pustular (von Zumbusch), guttate, or palmoplantar psoriasis
- History of an allergic reaction or known and/or significant sensitivity to study drug
The study team makes the final eligibility decision.
Where it is enrolling
- Glendale, Arizona, United States
- Fremont, California, United States
- Miami, Florida, United States
- Indianapolis, Indiana, United States
- Portsmouth, New Hampshire, United States
- Rochester, New York, United States
- Wilmington, North Carolina, United States
- San Antonio, Texas, United States
- Webster, Texas, United States
- Spokane, Washington, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 65 years. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Glendale, Arizona, United States; Fremont, California, United States; Miami, Florida, United States; Indianapolis, Indiana, United States; Portsmouth, New Hampshire, United States; Rochester, New York, United States and 4 more locations. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.